Meeting
2016 Gastrointestinal Cancers Symposium
A phase II study of bevacizumab in combination with irinotecan plus S-1 as first-line treatment in patients with KRAS mutant-type metastatic colorectal cancer.
Authors
Tetsuya Eto
Tsuchiura Kyodo General Hospital, Ibaraki, Japan
Tetsuya Eto , Toshiki Masuishi , Kohei Suzuki , Isamu Shibata , Yuichi Fukami , Toru Matsui , Takashi Ichida , Fumihiko Kusano , Junichi Tazawa , Yoshinori Sakai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000004630
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 676)
DOI
10.1200/jco.2016.34.4_suppl.676
Abstract #
676
Poster Bd #
J15
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
First Author: Satoshi Yuki
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC).
First Author: Daniel H. Ahn
Poster
2019 Gastrointestinal Cancers Symposium
A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
First Author: Sotaro Sadahiro